Toshifumi Yodoshi1, Sarah Orkin1, Ana Catalina Arce-Clachar1,2, Kristin Bramlage1, Weizhe Su3, Lin Fei2,4, Stavra A Xanthakos1,2, Marialena Mouzaki1,2. 1. Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 3. Department of Mathematical Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 4. Division of Biostatistics and Epidemiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abstract
BACKGROUND: A subset of patients with nonalcoholic steatohepatitis (NASH) respond to treatment with vitamin E. The characteristics of responders are not known. The objective of this study was to investigate the outcomes of vitamin E use in clinical practice and to determine factors associated with response to treatment. METHODS: A pediatric cohort with NASH treated with vitamin E for 6-24 months was studied retrospectively. Vitamin E response was defined as alanine aminotransferase (ALT) normalization or >50% ALT reduction from baseline. Univariate and multivariate logistic regression was used to determine the predictors of response to vitamin E. Available paired liver biopsy data were analyzed to determine histologic response. RESULTS: Of the 151 children prescribed vitamin E, 73 met inclusion/exclusion criteria. Of those, 28 (38%) were vitamin E responders. Higher baseline serum alkaline phosphatase (ALP) levels, steatosis grade, and Nonalcoholic Fatty Liver Disease Activity Score (NAS) were associated with response to vitamin E (ALP: odds ratio [OR], 14.1; 95% CI, 1.7-118.6; steatosis: OR 2.5; 95% CI, 1.2-5.0; NAS: OR 1.6; 95% CI, 1.1-2.4). In a multivariate logistic regression model, ALP and steatosis grade rendered an area under the curve of 0.75 (P < .001) for the prediction of response to treatment. Ballooning, NAS, and portal inflammation improved significantly with vitamin E in the subcohort (n = 15) with paired liver biopsies. CONCLUSIONS: Vitamin E treatment was associated with significant ALT response in 38% of children. Baseline serum ALP levels and steatosis grade were associated with response to treatment.
BACKGROUND: A subset of patients with nonalcoholic steatohepatitis (NASH) respond to treatment with vitamin E. The characteristics of responders are not known. The objective of this study was to investigate the outcomes of vitamin E use in clinical practice and to determine factors associated with response to treatment. METHODS: A pediatric cohort with NASH treated with vitamin E for 6-24 months was studied retrospectively. Vitamin E response was defined as alanine aminotransferase (ALT) normalization or >50% ALT reduction from baseline. Univariate and multivariate logistic regression was used to determine the predictors of response to vitamin E. Available paired liver biopsy data were analyzed to determine histologic response. RESULTS: Of the 151 children prescribed vitamin E, 73 met inclusion/exclusion criteria. Of those, 28 (38%) were vitamin E responders. Higher baseline serum alkaline phosphatase (ALP) levels, steatosis grade, and Nonalcoholic Fatty Liver Disease Activity Score (NAS) were associated with response to vitamin E (ALP: odds ratio [OR], 14.1; 95% CI, 1.7-118.6; steatosis: OR 2.5; 95% CI, 1.2-5.0; NAS: OR 1.6; 95% CI, 1.1-2.4). In a multivariate logistic regression model, ALP and steatosis grade rendered an area under the curve of 0.75 (P < .001) for the prediction of response to treatment. Ballooning, NAS, and portal inflammation improved significantly with vitamin E in the subcohort (n = 15) with paired liver biopsies. CONCLUSIONS:Vitamin E treatment was associated with significant ALT response in 38% of children. Baseline serum ALP levels and steatosis grade were associated with response to treatment.
Authors: Jeffrey B Schwimmer; Cynthia Behling; Robert Newbury; Reena Deutsch; Caroline Nievergelt; Nicholas J Schork; Joel E Lavine Journal: Hepatology Date: 2005-09 Impact factor: 17.425
Authors: Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos Journal: J Pediatr Gastroenterol Nutr Date: 2017-02 Impact factor: 2.839
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck Journal: JAMA Date: 2011-04-27 Impact factor: 56.272
Authors: Warren L Shapiro; Elizabeth L Yu; Jennifer C Arin; Karen F Murray; Sabina Ali; Nirav K Desai; Stavra A Xanthakos; Henry C Lin; Naim Alkhouri; Reham Abdou; Stephanie H Abrams; Megan W Butler; Sarah A Faasse; Lynette A Gillis; Timothy A Hadley; Ajay K Jain; Marianne Kavan; Kattayoun Kordy; Peter Lee; Jennifer Panganiban; John F Pohl; Carol Potter; Bryan Rudolph; Shikha S Sundaram; Shivali Joshi; James A Proudfoot; Nidhi P Goyal; Kathryn E Harlow; Kimberly P Newton; Jeffrey B Schwimmer Journal: J Pediatr Gastroenterol Nutr Date: 2019-02 Impact factor: 2.839
Authors: Elizabeth J Mayer-Davis; Anna R Kahkoska; Craig Jefferies; Dana Dabelea; Naby Balde; Chun X Gong; Pablo Aschner; Maria E Craig Journal: Pediatr Diabetes Date: 2018-10 Impact factor: 4.866